健脾益肾降浊方治疗糖尿病肾病的临床疗效及对患者微炎症状态的影响  

Clinical efficacy of Jianpi Yishen Jiangzhuo Formula for diabetic kidney disease and its influence on micro-inflammation status

作　　者：赵惠叶 刘红利 田金悦[1] 李洋 赵重阳 ZHAO Huiye;LIU Hongli;TIAN Jinyue;LI Yang;ZHAO Chongyang(Department of Traditional Chinese Medicine for Diabetes,Shijiazhuang Second Hospital,Shijiazhuang,Hebei 050035;Shijiazhuang Technology Innovation Center for Precision Diagnosis and Treatment of Diabetes,Shijiazhuang,Hebei 050035;Hebei Provincial Key Laboratory of Basic Medicine for Diabetes,Shijiazhuang,Hebei 050035;Department of Pediatrics,TCM Hospital of Shijiazhuang City,Shijiazhuang,Hebei 050011)

机构地区：[1]河北省石家庄市第二医院糖尿病中医科,河北石家庄050035 [2]河北省石家庄市糖尿病精准诊疗技术创新中心,河北石家庄050035 [3]河北省糖尿病基础医学研究重点实验室,河北石家庄050035 [4]河北省石家庄市中医院儿科,河北石家庄050011

出　　处：《河北中医》2024年第1期41-45,共5页Hebei Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局2020年度中医药类科研计划课题(编号:2020276)。

摘　　要：目的观察健脾益肾降浊方治疗糖尿病肾病(DKD)的临床疗效及对患者微炎症状态的影响。方法选取2020年1月至2021年3月收治的80例DKD患者为研究对象,按照随机数字表法分为2组,对照组40例予西医常规治疗,治疗组40例在对照组基础上联合健脾益肾降浊方治疗。2组均治疗12周后统计疗效,比较2组患者治疗前后血糖指标[包括空腹血糖(FPG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA_(1)c)]、炎症指标[包括超敏C反应蛋白(hs-CRP)、白细胞介素8(IL-8)、IL-6及肿瘤坏死因子α(TNF-α)]、肾功能指标[包括血肌酐(SCr)、尿素氮(BUN)及尿白蛋白排泄率(UAER)]及中医症状评分变化情况。结果与本组治疗前比较,2组治疗后血糖指标FPG、2 hPG及HbA_(1)c水平均下降(P<0.05),但2组治疗后FPG、2 hPG及HbA_(1)c组间比较差异无统计学意义(P>0.05)。与本组治疗前比较,2组治疗后炎症指标hs-CRP、IL-8、IL-6及TNF-α水平均降低(P<0.05),且治疗组治疗后hs-CRP、IL-8、IL-6及TNF-α水平均低于对照组(P<0.05)。与本组治疗前比较,2组治疗后肾功能指标SCr、BUN及UAER水平均降低(P<0.05),且治疗组治疗后肾功能指标SCr、BUN及UAER水平均低于对照组(P<0.05)。与本组治疗前比较,2组治疗后中医症状评分均降低(P<0.05),且治疗组治疗后中医症状评分低于对照组(P<0.05)。治疗组总有效率87.5%(35/40),对照组总有效率62.5%(25/40),治疗组总有效率高于对照组(P<0.05)。结论健脾益肾降浊方治疗DKD临床疗效确切,可有效改善患者微炎症状态,提高肾功能,改善中医症状,从而减慢疾病进展,安全可靠。Objective To observe the clinical efficacy of Jianpi Yishen Jiangzhuo Formula for diabetic kidney disease(DKD)and its influence on micro-inflammation status.Methods From January 2020 to March 2021,a total of 80 DKD patients were randomly assigned into the treatment group(n=40)and the control group(n=40).All patients were managed by routine Western medicine,and those in the treatment group were additionally treated with Jianpi Yishen Jiangzhuo Formula.Treated for 12 weeks,the aim was to compare blood glucose indexes(fasting plasma glucose[FPG],2-h postprandial glucose[2 hPG],glucose hemoglobin[HbA_(1)c]),inflammatory indexes(High-sensitivity C-reactive protein[hs-CRP],interleukin 8[IL-8],IL-6,tumor necrosis factor alpha[TNF-α]),renal function indexes(serum creatinine[Scr],blood urea nitrogen[BUN],urinary albumin excretion rate[UAER]),traditional Chinese medicine(TCM)symptom score.The curative effect was assessed.Results After treatment,FPG,2 hPG and HbA_(1)c in the both groups were significantly decreased compared those before treatment(P<0.05),but with no statistically significant difference between the treatment group and the control group(P>0.05).After treatment,hs-CRP,IL-8,IL-6,TNF-αin the both groups were significantly decreased(P<0.05),which decreased notably in the treatment group compared with the control group(P<0.05).SCr,BUN and UAER in the both groups were significantly decreased(P<0.05),the reduction in the treatment group was more prevalent compared with the control group(P<0.05).TCM symptom scores in the both groups were significantly decreased(P<0.05),the decrease in the treatment group was more common than the control group(P<0.05).The overall effective rate in the treatment group was better than that in the control group(87.5%[35/40]vs 62.5%[25/40],[P<0.05],respectively).Conclusion For DKD patients,Jianpi Yishen Jiangzhuo Formula has definite clinical efficacy,which can effectively improve micro-inflammation status,kidney function,TCM symptoms,thereby slowing down disease progression,and with sa

关 键 词：糖尿病肾病 中药疗法 健脾益肾 微炎症 

分 类 号：R587.24[医药卫生—内分泌]